NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN)

NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).

Ranolazine Shortens QT Interval and improves Cardiac Relaxation in Patients With Long QT Syndrome

CV Therapeutics have announced results that show ranolazine significantly shortens the QT interval of patients with a hereditary form of long QT syndrome called LQT3. Ranolazine also shortened cardiac relaxation time in the study.

FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Evotec/Pfizer initiate Phase I trial of VR1 antagonist

Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist in collaboration with Pfizer

CV therapeutics announce FDA is continuing review of Ranexa for Angina

CV Therapeutics have announced that the FDA is continuing its review of Ranexa (ranolazine extended-release tablets) even though the PDUFA action date of July 27, 2008 has been met. The drug is under review for first line treatment of chronic angina and a significant reduction in cautionary language, based on substantial data from the MERLIN [...]

Ranolazine receives EU marketing authorization for Chronic Angina

CV Therapeutics have announced that the EMEA has granted approval for ranolazine in the treatment of patients with chronic angina in all 27 European Union (EU) member states.

Cleviprex effective in the treatment of Acute Hypertension After Cardiac Surgery

Phase III data shows that The Medicines Company’s drug Cleviprex (clevidipine butyrate) is effective and safe in the rapid treatment of acute hypertension after cardiac surgery.

Merck publish series of novel T-type Ca channel antagonists

Merck have published a series of novel T-type Ca channel antagonists. Compounds displayed in vivo CNS efficacy without adverse cardiovascular effects

Banyu Scientists describe Opioid Receptor Like 1 Antagonists with affinity to the hERG K+ Channel

Banyu Scientists have described a series of Opioid Receptor Like 1 (ORL1) antagonists with affinity to the hERG K Channel

Acordas Fampridine-SR shows efficacy in Multiple Sclerosis

Phase III data show that Acorda Therapeutic’s Potassium channel blocker Fampridine-SR improved walking ability in people with multiple sclerosis.